FDA approves Genentech’s SUSVIMO, a first-of-its-kind therapeutic approach for wet age-related macular degeneration (AMD)

Genentech announced on October 22 that the U.S. Food and Drug Administration (FDA) has approved SUSVIMO™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.